MedTrace Logo

Intracranial Pressure and a Potential Vicious Circle of Atrial Fibrillation in HFpEF

NCT07521293 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 309

Last updated 2026-04-09

No results posted yet for this study

Summary

This study was designed to investigate predictors of atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF), with a particular focus on the potential relationship between venous congestion and intracranial pressure dynamics. Among HFpEF patients, those with AF exhibited significantly higher right atrial pressure (RAP), larger right atrial area, higher CHA₂DS₂-VA scores, and increased optic nerve sheath diameter (ONSD), a noninvasive surrogate marker of intracranial pressure. In multivariable logistic regression analysis, increased ONSD, elevated RAP, larger right atrial area, and higher CHA₂DS₂-VA score remained independently associated with AF, suggesting that both systemic venous congestion and intracranial pressure-related mechanisms may contribute to AF susceptibility in this population. These findings support the hypothesis of a cardio-cerebral interaction in HFpEF, in which elevated right-sided filling pressures may impair cerebrospinal fluid drainage, increase intracranial pressure, and potentially promote AF through autonomic and hemodynamic pathways.

Conditions

  • Heart Failure With Preserved Ejection Fraction (HFpEF)
  • Atrial Fibrillation
  • Optic Nerve Sheath Diameter
  • Intracranial Pressure
  • Venous Congestion

Interventions

DIAGNOSTIC_TEST

Echocardiography

Standard transthoracic echocardiography, including EF, E/e', TRV, atrial areas, SPAP, and estimated right atrial pressure.

Sponsors & Collaborators

  • Ankara Ataturk Sanatorium Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • şahbender koç, MD · AnkaraAtatürk STRH

Eligibility

Min Age
60 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-14
Primary Completion
2026-03-20
Completion
2026-03-20

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07521293 on ClinicalTrials.gov